ESC 365 - Cost-effectiveness of Sacubitril/Valsartan in acute and chronic heart failure with reduced ejection fraction: from randomized controlled trials to real-world evidence

HFA Premium Access

Cost-effectiveness of Sacubitril/Valsartan in acute and chronic heart failure with reduced ejection fraction: from randomized controlled trials to real-world evidence

Session: ePosters in acute heart failure 7

Topic: Pharmacotherapy

Speaker: Doctor Y. Lin (Tainan, TW)

Event: Heart Failure 2023

Congress Presentation

Add to my library

About the speaker

Doctor Yu-Min Lin

Chi-Mei Medical Center, Tainan (Taiwan)

1 follower

4 more presentations in this session

Clinical presentation, shock severity and mortality in patients with de novo vs. acute-on-chronic heart failure-related cardiogenic shock

Speaker: Doctor J. Sundermeyer (Hamburg, DE)

Analysis of the implantation of heart failure with reduced ejection fraction treatment in clinical practice and its impact on achieving target doses

Speaker: Doctor A. Esteban Fernandez (Leganes, ES)

Role of specialised heart failure unit in optimisation of guideline-directed medical therapy - real world data

Speaker: Doctor E. Macken (London, GB)

Diabetes predicts in-hospital outcomes in men but not in women with acute myocardial infarction

Speaker: Doctor A. Poniku (Pristina, XK)

Access the full session

ePosters in acute heart failure 7

Speakers: Doctor Y. Lin, Doctor J. Sundermeyer, Doctor A. Esteban Fernandez, Doctor E. Macken, Doctor A. Poniku

About the event

Heart Failure 2023

20 May - 23 May 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources